GEORGE WHITNEY

*** ********** **** 215-***-**** Mobile

NEWTOWN, PA. 18940 ad018p@r.postjobfree.com

EDUCATION Master’s Degree - Trenton State College (Ewing, NJ), 1990.

Master’s Thesis - Development of a Hybridoma Cell Line Directed Against the TAX Peptide.

BS in Biology - Stockton State College (Pomona, NJ), 1981.

KEY ACHIEVEMENTS

Strong knowledge of the Biopharmaceutical, Cell Culture Media Formulation, Human Nutritional, and Pharmaceutical industries from a business stand-point as well M&A, JV, and global strategic partnerships.

Goals oriented, with a proven track record of success over forty-two (42) years in the industry.

Successfully met or exceeded budgetary goals over the past twenty-nine (29) years in Business Development and Sales positions.

Strong technical background in upstream, downstream and drug delivery for the Biotechnology, Biopharmaceutical, and Pharmaceutical Industries.

Successfully managed Process Development groups for scale-up and clinical manufacturing for vaccines, monoclonal antibodies, and drug delivery applications.

Experience in developing chemically-defined cell culture media formulations.

Technical and Commercial experience with T-Cell and Gene Therapy applications.

Experience working with CHO-K1, NS0, and HEK-293 cell lines.

Experience with development and supply of viral vectors, fusion proteins, and synthetic DNA/RNA applications.

Technical and sales experience for small molecule drugs applications.

Highly motivated with excellent communication skills

Extensive experience with CRM systems to improve knowledge and communications regarding customer and competitor information.

EXPERIENCE

Daesang America Hackensack, NJ, 07601

3/01/2021 to 06/30/23, Technical Sales Manager for N. America

My responsibilities for Daesang America included the development of the amino acid markets for Biopharmaceutical, Cell Culture Media Formulation, Medical Foods, and Human/Infant Nutritional industries. Territory covered, N. America. Additionally, I am a key contributor to M&A, JV, and potential Marketing Agreement,

report directly to the President and CEO of Daesang America as well communicate regularly with our S. Korean Head Quarters.

Annual target sales are $1MM, annual achieved sales are $1.5MM - $2MM.

Spectrum Chemical Corp. New Brunswick, NJ, 08901

10/01/2020 to 3/1/2021 Biopharmaceutical Development Manager

As the Biopharmaceutical Development Manager, I was responsible to develop new BioPharma/Cell Culture Media opportunities for current and new customers as well as establish a consistent upstream and downstream raw materials supply system to support the growing markets for Spectrum Chemical, for the manufacture of large molecule and small molecule drug products. Territory covered was N. America.

Annual target sales were $2MM, sales achieved in 4 months was $750K.

Fujifilm Irvine Scientific Santa Ana, CA, 92705

5/11/2020 to 9/30/2020 Territory Manager for Mid-Atlantic Region

As Territory Manager, my responsibilities included the identification and development of new accounts/business opportunities for upstream and downstream production of vaccines, monoclonal antibodies, gene therapy, and cell therapy drug products, to Biotechnology, Biopharmaceuticals, and Pharmaceutical applications. Additionally, I am responsible for managing current and future business in Delaware, Pennsylvania, New Jersey, and New York.

Target annual sales were $6MM, sales achieved $6.5M.

Kyowa Hakko USA, Inc. New York, NY 10016

3/2010 to 12/2019 Director Business Development/Sales for North America

As Director of Business Development and Sales for the Biopharmaceutical and Pharmaceutical markets, I reported directly to President and CEO for Kyowa Hakko USA. My primary focus was to develop strategic relationships with key accounts and to expand the relationships on a global basis. Kyowa Hakko USA, a subsidiary of Kyowa Hakko Kirin (Tokyo, Japan), supplies API, Drug Intermediates, Excipients, and Critical Raw Materials to Biopharmaceutical, Cell Culture Media Formulation, Infusion, Pharmaceutical, Medical Foods and Nutritional Industries.

In addition to directing Sales activities for the Biopharmaceutical, Cell Culture Media Formulation, Infusion, and Pharmaceutical Industries, I was responsible for the development

of new business opportunities relating to new products under development at Kyowa Hakko as well as identify new business opportunities for presentation to the R&D and Upper Management at Kyowa Hakko for consideration.

Additionally, I was responsible for the identification, contract negations, and project management of peptides and other key ingredients used to produce vaccines and monoclonal antibodies with CDMO companies. I was also a member of Kyowa Hakko’s Strategic Initiative team that is responsible for establishing the Global Strategy for Kyowa Hakko’s Biopharmaceutical, Pharmaceutical and Human Nutritional, including media foods and sprots nutritional markets.

Territory covered N. America and key Global Accounts.

Annual sales targets were $16MM, annual sales achieved were $21MM

Lonza Inc. Allendale, NJ 07401

10/2007 to 3/2010 Associate Director Sales and Business Development

As Associate Director and a member of the Lonza Custom Manufacturing group, reporting directly to the Vice President of Sales and Business Development, my responsibilities included developing business opportunities relating to all sectors of Lonza. These business sectors included Biologics (mammalian and microbial), Biochemicals, Custom Synthesis (peptides and small molecules), cell line development, cell banking, and Drug Conjugates. My key account responsibilities involved the development of new business opportunities as well as managing logistics and planning for twenty-eight Biopharmaceutical, Pharmaceutical, and Human Nutritional/Sports Nutritional accounts located on the USA’s East Coast. The majority of my account base utilized Lonza’s Global Development and Manufacturing network.

Annual target sales were $20MM, annual sales achieved were $28MM.

Ajinomoto AminoScience LLC Raleigh, NC 27610

3/2004 to 10/2007 Associate Director Biopharmaceutical Sales

As Associate Director Biopharmaceutical Sales for Ajinomoto AminoScience, reporting to the President of Ajinomoto AminoScience, I was responsible for development and implementation of Sales and Marketing activities in North America that pertain to the Biopharmaceutical Industry, Pharmaceutical, and Human Notional/Sports Nutrition. Ajinomoto (global headquarters in Tokyo, Japan) is one of the global leading manufacturers of amino acids for use in the Biotech, Pharmaceutical, Nutritional, and Food Industries. I had two direct reports, one outside account manager, and one consultant, responsible for approximately 150 accounts. Additionally, I had account management responsibilities for key global accounts.

In addition to directing Sales activities and managing key global accounts, I was also responsible for generating vital market segment information, which included the development of new markets, upstream and downstream applications, for existing technologies and the launch of new products for biopharmaceutical applications.

I was also responsible for identifying, contract negations, and project management for the development and production of peptides and other key ingredients used to produce large molecule drug products such as monoclonal antibodies, r-proteins, vaccines, human nutritional and sports nutrition applications.

Territory covered was N. America and key Global Accounts.

Annual target sales were $15MM, annual achieved sales were $20MM.

Ajinomoto AminoScience LLC Raleigh, NC 27610

10/2001 to 3/2004 Eastern Regional Sales Manager

As Eastern Regional Sales Manager for Ajinomoto AminoScience, I was responsible for business

development and account management for Biotechnology and Pharmaceutical accounts located in the Unities States, Canada, and Puerto Rico. My sales activities required interaction with Procurement/Sourcing as well as Process Development and Production individuals up to the level of President.

I was actively involved in the marketing activities for the amino acid division. The activities included the development of our first product catalog, creation of exhibit booth graphics for exhibition at scientific conferences, and the establishment of scientific workshops for private industry as well as scientific conferences. My customer base was strictly industrial and involved key accounts located in the USA and Canada.

Target annual sales were $10MM, annual achieved sales were $12MM.

Lexicon Pharmaceuticals, Inc., East Windsor, NJ 08520

5/2001 to 10/2001 Sales and Marketing Manager

As Sales & Marketing Manager I was responsible for all aspects of global sales and marketing of

compound libraries and follow-up services to the Pharmaceutical and Biotechnology Industries. Lexicon Pharmaceuticals (formerly Coelacanth Corp.) designs and produces novel, targeted compound libraries from drug-like building blocks, for use in drug discovery applications. Lexicon Pharmaceuticals was the result of the merger between Coelacanth Corp. (E. Windsor, NJ) and Lexicon Genetics (Woodlands, TX).

Sigma-Aldrich Corporation, St. Louis, MO 63103

9/1996 to 5/2001 Account Manager – Sigma-Aldrich Fine Chemicals Division

As an Account Manager for SAFC, the industrial sales division of the Sigma-Aldrich Corp., I was

responsible for the generation of sales, as well as development of new business opportunities, in my key accounts within my geographical territory (NY, NJ, PA, DE, MD, VA, NC, and GA). My territory also included key accounts in the following states NH, MA, and WA. Those accounts were involved in pre-clinical through commercial manufacturing of therapeutic drugs, diagnostic drugs, nutraceuticals. Additionally, I was also involved in Proof-of-Principle projects within my key accounts. The customer base, for which I was responsible, developed and manufactured products for the human, veterinary, agricultural, human nutritional industries.

The specific areas of concentration in key accounts included Upstream (cell culture/fermentation), Downstream (purification), Key Intermediates, Excipients, Active Pharmaceutical Ingredients, and Final Formulations. While working within each of the aforementioned areas, I routinely interacted with individuals in the R&D, Process Development, Manufacturing, Quality Systems, Regulatory and Procurement divisions of an organization. That interaction required intimate knowledge of technical, cGMP, Quality and Regulatory requirements.

Approximately 70% of the projects within my key account base were considered custom projects. Those projects consisted of custom formulations, custom synthesis, custom testing or custom packaging for delivery of approved material. These custom projects required my close interaction with the following departments within the Sigma-Aldrich Corporation: R&D, Development, Manufacturing, Quality Control, Quality Assurance, Packaging, Shipping and Customer Service.

Target annual sales were $6MM, achieved annual sales were $7MM.

JRH Biosciences, Lenexa, KS 66215

11/1993 to 9/1996 Account Manager/Sales and Marketing

As an Account Manager, I was responsible for the daily maintenance of my territory, as well as the

development of new business opportunities in both existing as well as new accounts.

JRH Biosciences' primary focus was the sale of sera and tissue culture media to the Biopharmaceutical Industry for the development and manufacture of monoclonal antibodies and vaccines. My customer base consisted of industrial accounts, from start-up R&D groups through established pharmaceutical houses. My territory responsibilities extended from New York to Florida.

Target annual sales were $5MM, Achieved annual sales were $6MM

The Liposome Company, Inc., Princeton, NJ 08540

1/1992 to 11/1993 Manager/Process Development

As manager of Process Development, my responsibilities included

As Process Development Manager, my responsibilities included design, and procurement of capital equipment related to the production of liposomal-based therapeutic agents. As Manager of the Process Development group I had 4 direct reports, two Chem-E PhD’s and two Research Associates with BS degrees. The Process Development group provided bi-directional transfer of scale-up information between Formulations and Clinical Manufacturing groups for lipid and liposomal-based therapeutic agents.

Additionally, the PD group developed and executed validation protocols for all new process equipment used for the production and final filling of lipid and liposomal-based therapeutic agents.

CYTOGEN Corporation, Princeton, NJ. 08540

7/1991 to 1/1992 Manager/Biofermentation

As Manager of Biofermentation, my responsibilities included managing all aspects of the up-stream

process for the production of clinical-grade monoclonal antibodies. Additionally, I was responsible for managing the up-stream Process Development group for monoclonal antibodies. This included the development and scale-up of bioreactor processes for MAb production, as well as develop and optimize methodology for the establishment of serum-free cell banks. As Manager of the Biofermentation group I had four direct reports, one Research Scientist, two Research Associates and one Research Assistant.

CYTOGEN Corporation, Princeton, NJ 08540

1/1990 to 7/1991 Research Scientist/Biofermentation

Responsibilities:

Supervisor for the In vitro Monoclonal Antibody Production Laboratory, in which clinical- grade monoclonal antibody is manufactured under GMP conditions using automated, state-of-the-art, bioreactor systems.

Coordination of all process validation for Biofermentation.

Development of serum-free media for Murine hybridoma, and CHO-K1 cell lines.

Adaptation of Murine hybridoma lines to growth under serum-free conditions.

The establishment of cell banks for use in the production of clinical monoclonal antibody.

The establishment of Post Production Cell Banks from each Production lot of monoclonal antibody produced in a bioreactor.

Process Development/Process Optimization for the in vitro production of monoclonal antibody in various bioreactor systems. These bioreactor systems range from stirred tank, fluidized bed, hollow fibers, or ceramic matrix systems.

Schedule all required outside testing for cell banks and in-process material.

Develop all documentation (Master Batch Record, Standard Operating Procedures,

Raw Materials Purchase and Release Specifications, Validation Protocols and Test

Procedures) that pertains to the In vitro Monoclonal Antibody Production Area.

Training of personnel on the operation of bioreactor systems.

Establish and coordinate extramural projects (i.e. contract production of either in vivo or in vitro derived monoclonal antibody) for antibody production.

Perform vendor site audits in conjunction with the Quality Assurance Department.

CYTOGEN Corporation, Princeton, NJ 08540

5/1987 to 1/1990 Research Associate/Cell Biology;

Responsibilities:

Feasibility studies involving the implementation of bioreactors for in vitro production of monoclonal antibodies to support pre-clinical projects.

Identify an appropriate bioreactor technology to accommodate the corporation's intermediate (1 to 5 years) needs.

Design a GMP facility to accommodate the bioreactor technology of choice.

Antibody Purification

Maintenance of human tumor cell lines.

PITMAN-MOORE, Inc., Titusville, NJ, 08560

1/1984 to 5/1987 Process Development Specialist/Vaccine Production

Responsibilities:

Conversion of existing vaccine production in conventional roller bottles to production in bioreactor systems. This required the conversion of four separate established cell lines and ten separate viruses to growth and production in a continuously perfused bioreactor

system.

Development of all supporting documentation for the conversion of vaccine production to bioreactor systems.

Training of production personnel for vaccine production in bioreactor systems.

Scale-up of new products from research to production.

:

PITMAN-MOORE, Inc. Titusville, NJ 08560

8/1981 to 1/1984 Tissue Culture/Vaccine Processing Technician

Contact this candidate